WO2024259323A3 - Compositions pharmaceutiques pour administration ciblée d'agents bioactifs à biodisponibilité améliorée et méthodes d'utilisation - Google Patents

Compositions pharmaceutiques pour administration ciblée d'agents bioactifs à biodisponibilité améliorée et méthodes d'utilisation Download PDF

Info

Publication number
WO2024259323A3
WO2024259323A3 PCT/US2024/034128 US2024034128W WO2024259323A3 WO 2024259323 A3 WO2024259323 A3 WO 2024259323A3 US 2024034128 W US2024034128 W US 2024034128W WO 2024259323 A3 WO2024259323 A3 WO 2024259323A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
targeted delivery
bioactive agents
methods
improved bioavailability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/034128
Other languages
English (en)
Other versions
WO2024259323A2 (fr
Inventor
Scott Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2024259323A2 publication Critical patent/WO2024259323A2/fr
Publication of WO2024259323A3 publication Critical patent/WO2024259323A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions thérapeutiques et pharmaceutiques pour une application topique et une administration ciblée d'agents bioactifs ayant une biodisponibilité de médicament améliorée à un sujet, la composition comprenant i) un support anhydre; ii) une quantité efficace d'un agent bioactif; et iii) un activateur de pénétration choisi dans le groupe constitué par un composé dérivé d'acide aminé, un peptide de pénétration cellulaire (CPP), un peptide antimicrobien, une composition de nanoparticules lipidiques et des combinaisons de ceux-ci.
PCT/US2024/034128 2023-06-14 2024-06-14 Compositions pharmaceutiques pour administration ciblée d'agents bioactifs à biodisponibilité améliorée et méthodes d'utilisation Pending WO2024259323A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508175P 2023-06-14 2023-06-14
US63/508,175 2023-06-14

Publications (2)

Publication Number Publication Date
WO2024259323A2 WO2024259323A2 (fr) 2024-12-19
WO2024259323A3 true WO2024259323A3 (fr) 2025-01-23

Family

ID=93852837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034128 Pending WO2024259323A2 (fr) 2023-06-14 2024-06-14 Compositions pharmaceutiques pour administration ciblée d'agents bioactifs à biodisponibilité améliorée et méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2024259323A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140171490A1 (en) * 2005-02-07 2014-06-19 Pharmalingt Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20160199498A1 (en) * 2013-08-12 2016-07-14 3M Innovative Properties Company Peptides for enhancing transdermal delivery
US20200009040A1 (en) * 2017-02-07 2020-01-09 Myocept Inc. Topical formulations and methods
US10806790B1 (en) * 2013-11-12 2020-10-20 Scott Shapiro Pain therapy cream with deep tissue delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140171490A1 (en) * 2005-02-07 2014-06-19 Pharmalingt Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20160199498A1 (en) * 2013-08-12 2016-07-14 3M Innovative Properties Company Peptides for enhancing transdermal delivery
US10806790B1 (en) * 2013-11-12 2020-10-20 Scott Shapiro Pain therapy cream with deep tissue delivery system
US20200009040A1 (en) * 2017-02-07 2020-01-09 Myocept Inc. Topical formulations and methods

Also Published As

Publication number Publication date
WO2024259323A2 (fr) 2024-12-19

Similar Documents

Publication Publication Date Title
Hartmann et al. Toxicity of platinum compounds
US10888622B2 (en) Nanocomplexes of modified peptides or proteins
AU2011227083B2 (en) Stable bortezomib formulations
US8263578B2 (en) Stable bortezomib formulations
SA517381446B1 (ar) تركيبات مضاد حيوي
Cheng et al. Signed, sealed, delivered: conjugate and prodrug strategies as targeted delivery vectors for antibiotics
EP1478372B1 (fr) Composition anti-parasitaire longue duree contenant un compose salicylanilide, une espece polymerique et au moins un autre compose anti-parasite
US20110245501A1 (en) Substituted Tetracycline Compounds as Synergistic Antifungal Agents
WO2006017251A3 (fr) Compositions pour l'apport du peptide yy et d'agonistes du pyy
CA2492976A1 (fr) Solution destinee a une application ungueale et peri-ungueale
WO2004104018A3 (fr) Compostions d'administration de peptide yy de d'agonistes pyy
DK2143429T3 (en) Use of cilastatin for reducing the nephrotoxicity of various compounds
WO2005028516A3 (fr) Nouvelles etiquettes d'affinite pour les proteines plasmiques
KR20150034685A (ko) 국소 비수성 약학 제형물
US11590233B2 (en) Porphyrin compounds and compositions useful for treating cancer
Nudelman Mutual prodrugs-codrugs
US20230105108A1 (en) Compounds for the treatment of bacterial infections and potentiation of antibiotics
WO2024259323A3 (fr) Compositions pharmaceutiques pour administration ciblée d'agents bioactifs à biodisponibilité améliorée et méthodes d'utilisation
US10125167B2 (en) Compositions and methods for treating MRSA infections and for sensitizing MRSA to beta-lactam antibiotics
AU2004257450B2 (en) Parasiticidal composition
CZ287896B6 (cs) Antimikrobiálně účinné směsi, léčiva tyto látky obsahující a jejich použití
US20040166148A1 (en) Transdermal therapeutic delivery systems with a butenolide
US10835615B2 (en) Supramolecular hydrogels containing angiotensin receptor blockers for targeted treatment of diabetic wounds
JPH04506056A (ja) ペプチド組合せ組成物及びその用法
US8697712B2 (en) Presentation of an antiviral pharmaceutical composition

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2024824277

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824277

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114

ENP Entry into the national phase

Ref document number: 2024824277

Country of ref document: EP

Effective date: 20260114